Anti-Inflammatory Therapy Modulates Nrf2-Keap1 in Kidney from Rats with Diabetes

Oxidative Medicine and Cellular Longevity

Volumn 2016, Issue , 2016, Pages

  Arellano Buendía, Abraham Said ^a,b   Tostado González, Montserrat ^a,b   García Arroyo, Fernando Enrique ^a,b   Cristóbal García, Magdalena ^a,b   Loredo Mendoza, María Lilia ^c   Tapia, Edilia ^a,b   Sánchez Lozada, Laura Gabriela ^a,b   Osorio Alonso, Horacio ^a,b  

^a Laboratory of Renal Physiopathology   (Mexico)

^b INSTITUTO NACIONAL DE CARDIOLOGÍA IGNACIO CHÁVEZ   (Mexico)

^c UNIVERSIDAD PANAMERICANA   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIOXIDANTS; DISEASES; TISSUE;

ANTI-INFLAMMATORY EFFECTS; ANTIOXIDANT MECHANISMS; IMPAIRED RENAL FUNCTION; MYCOPHENOLATE MOFETIL; NUCLEAR TRANSLOCATIONS; PRO-INFLAMMATORY CYTOKINES; STRUCTURAL ALTERATIONS; TRANSFORMING GROWTH FACTORS;

OXIDATIVE STRESS;

ANTIINFLAMMATORY AGENT; AUTACOID; KEAP1 PROTEIN, RAT; KELCH LIKE ECH ASSOCIATED PROTEIN 1; MYCOPHENOLIC ACID; NFE2L2 PROTEIN, RAT; TRANSCRIPTION FACTOR NRF2;

ANIMAL; COMPLICATION; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEPHROPATHIES; DRUG EFFECTS; KIDNEY; MALE; METABOLISM; RAT; SIGNAL TRANSDUCTION; WISTAR RAT;

ANIMALS; ANTI-INFLAMMATORY AGENTS; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEPHROPATHIES; INFLAMMATION MEDIATORS; KELCH-LIKE ECH-ASSOCIATED PROTEIN 1; KIDNEY; MALE; MYCOPHENOLIC ACID; NF-E2-RELATED FACTOR 2; RATS; RATS, WISTAR; SIGNAL TRANSDUCTION;

EID: 84959422819     PISSN: 19420900     EISSN: 19420994     Source Type: Journal    
DOI: 10.1155/2016/4693801     Document Type: Article

References (33)

1. J. F. Navarro-González and C. Mora-Fernández, "The role of inflammatory cytokines in diabetic nephropathy," Journal of the American Society ofNephrology, vol. 19,no. 3, pp. 433-442, 2008.
2. P. E. Pergola, P. Raskin, R. D. Toto et al., "Bardoxolone methyl and kidney function in CKD with type 2 diabetes," The New England Journal of Medicine, vol. 365, no. 4, pp. 327-336, 2011.
3. H. J. Kim and N. D. Vaziri, "Contribution of impaired Nrf2-Keap1 pathway to oxidative stress and inflammation in chronic renal failure,"The American Journal of Physiology-Renal Physiology, vol. 298, no. 3, pp. F662-F671, 2010.
4. E. Galkina and K. Ley, "Leukocyte recruitment and vascular injury in diabetic nephropathy," Journal of the American Society of Nephrology, vol. 17, no. 2, pp. 368-377, 2006.
5. J. W. Seo, Y. G. Kim, S. H. Lee et al., "Mycophenolate mofetil ameliorates diabetic nephropathy in db/db mice," BioMed Research International, vol. 2015, Article ID 301627, 11 pages, 2015.
6. R. Utimura, C. K. Fujihara, A. L. Mattar, D. M. A. C. Malheiros, I. D. L. Noronha, and R. Zatz, "Mycophenolate mofetil prevents the development of glomerular injury in experimental diabetes," Kidney International, vol. 63, no. 1, pp. 209-216, 2003.
7. C. A. Feghali and T. M. Wright, "Cytokines in acute and chronic inflammation," Frontiers in Bioscience, vol. 2, pp. d12-d26, 1997.
8. K. Alexandraki, C. Piperi, C. Kalofoutis, J. Singh, A. Alaveras, and A. Kalofoutis, "Inflammatory process in type 2 diabetes: the role of cytokines," Annals of the New York Academy of Sciences, vol. 1084, pp. 89-117, 2006.
9. G. Hasegawa, K. Nakano, M. Sawada et al., "Possible role of tumor necrosis factor and interleukin-1 in the development of diabetic nephropathy," Kidney International, vol. 40, no. 6, pp. 1007-1012, 1991.
10. D. Suzuki,M. Miyazaki, R. Naka et al., "In situ hybridization of interleukin 6 in diabetic nephropathy," Diabetes, vol. 44, no. 10, pp. 1233-1238, 1995.
11. Q. Ma, L. Battelli, and A. F. Hubbs, "Multiorgan autoimmune inflammation, enhanced lymphoproliferation, and impaired homeostasis of reactive oxygen species in mice lacking the antioxidant-activated transcription factorNrf2,"American Journal of Pathology, vol. 168, no. 6, pp. 1960-1974, 2006.
12. K. Itoh, K. Igarashi, N. Hayashi, M. Nishizawa, and M. Yamamoto, "Cloning and characterization of a novel erythroid cellderived CNC family transcription factor heterodimerizing with the small Maf family proteins," Molecular and Cellular Biology, vol. 15, no. 8, pp. 4184-4193, 1995.
13. K. Itoh, N. Wakabayashi, Y. Katoh et al., "Keap1 represses nuclear activation of antioxidant responsive elements by Nrf2 through binding to the amino-terminal Neh2 domain," Genes &Development, vol. 13, no. 1, pp. 76-86, 1999.
14. A. Kobayashi, M.-I. Kang, H. Okawa et al., "Oxidative stress sensor Keap1 functions as an adaptor for Cul3-based E3 ligase to regulate proteasomal degradation of Nrf2," Molecular and Cellular Biology, vol. 24, no. 16, pp. 7130-7139, 2004.
15. B.-H. Choi, K.-S. Kang, and M.-K. Kwak, "Effect of redox modulating NRF2 activators on chronic kidney disease," Molecules, vol. 19, no. 8, pp. 12727-12759, 2014.
16. J.-M. Lee and J. A. Johnson, "An important role of Nrf2-ARE pathway in the cellular defense mechanism," Journal of Biochemistry and Molecular Biology, vol. 37, no. 2, pp. 139-143, 2004.
17. M. Song, E. K. Kim,W. S. Moon et al., "Sulphoraphane protects against cytokine and streptozotocin-induced beta-cell damage by suppressing theNF-kappaB pathway," Toxicology and Applied Pharmacology, vol. 235, no. 1, pp. 57-67, 2009.
18. A. S. Arellano-Buendá, F. E. Garcá-Arroyo, M. Cristóbal-Garcá et al., "Urinary excretion of neutrophil gelatinaseassociated lipocalin in diabetic rats," Oxidative Medicine and Cellular Longevity, vol. 2014,Article ID 961326, 11 pages, 2014.
19. M. M. Diaz Encarnacion, M. D. Griffin, J. M. Slezak et al., "Correlation of quantitative digital image analysis with the glomerular filtration rate in chronic allograft nephropathy," American Journal of Transplantation, vol. 4, no. 2, pp. 248-256, 2004.
20. Y.-G. Wu, H. Lin, X.-M. Qi et al., "Prevention of early renal injury by mycophenolate mofetil and its mechanism in experimental diabetes," International Immunopharmacology, vol. 6, no. 3, pp. 445-453, 2006.
21. Y. Wu, J. Dong, L. Yuan et al., "Nephrin and podocin loss is prevented by mycophenolate mofetil in early experimental diabetic nephropathy," Cytokine, vol. 44, no. 1, pp. 85-91, 2008.
22. Y. Zhang, B. Chen, X.-H. Hou et al., "Effects of mycophenolate mofetil, valsartan and their combined therapy on preventing podocyte loss in early stage of diabetic nephropathy in rats," Chinese Medical Journal, vol. 120, no. 11, pp. 988-995, 2007.
23. K. Yoh, A. Hirayama, K. Ishizaki et al., "Hyperglycemia induces oxidative and nitrosative stress and increases renal functional impairment in Nrf2-deficient mice," Genes to Cells, vol. 13, no. 11, pp. 1159-1170, 2008.
24. O.-H. Lee, A. K. Jain, V. Papusha, and A. K. Jaiswal, "An autoregulatory loop between stress sensors INrf2 and Nrf2 controls their cellular abundance," The Journal of Biological Chemistry, vol. 282, no. 50, pp. 36412-36420, 2007.
25. T. Jiang, Z. Huang, Y. Lin, Z. Zhang, D. Fang, and D. D. Zhang, "The protective role of Nrf2 in streptozotocin-induced diabetic nephropathy," Diabetes, vol. 59, no. 4, pp. 850-860, 2010.
26. Y. Tan, T. Ichikawa, J. Li et al., "Diabetic downregulation ofNrf2 activity via ERK contributes to oxidative stress-induced insulin resistance in cardiac cells in vitro and in vivo," Diabetes, vol. 60, no. 2, pp. 625-633, 2011.
27. X. He, H. Kan, L. Cai, and Q. Ma, "Nrf2 is critical in defense against high glucose-induced oxidative damage in cardiomyocytes," Journal of Molecular and Cellular Cardiology, vol. 46, no. 1, pp. 47-58, 2009.
28. J. Zhang, G. Johnston, B. Stebler, and E. T. Keller, "Hydrogen peroxide activates NFkappaB and the interleukin-6 promoter through NFkappaB-inducing kinase," Antioxidants and Redox Signaling, vol. 3, no. 3, pp. 493-504, 2001.
29. A. A. Elmarakby and J. C. Sullivan, "Relationship between oxidative stress and inflammatory cytokines in diabetic nephropathy," CardiovascularTherapeutics, vol. 30, no. 1, pp. 49-59, 2012.
30. D. D. Zhang, S.-C. Lo, Z. Sun, G. M. Habib, M. W. Lieberman, and M. Hannink, "Ubiquitination of Keap1, a BTB-Kelch substrate adaptor protein for Cul3, targets Keap1 for degradation by a proteasome-independent pathway," The Journal of Biological Chemistry, vol. 280, no. 34, pp. 30091-30099, 2005.
31. I. M. Copple, A. Lister, A. D. Obeng et al., "Physical and functional interaction of sequestosome 1 with Keap1 regulates the Keap1-Nrf2 cell defense pathway," The Journal of Biological Chemistry, vol. 285, no. 22, pp. 16782-16788, 2010.
32. A. K. Jain, S. Mahajan, and A. K. Jaiswal, "Phosphorylation and dephosphorylation of tyrosine 141 regulate stability and degradation of INrf2: A novel mechanism in Nrf2 activation," The Journal of Biological Chemistry, vol. 283, no. 25, pp. 17712-17720, 2008.
33. A. Gopalakrishnan and A.-N. Tony Kong, "Anticarcinogenesis by dietary phytochemicals: cytoprotection by Nrf2 in normal cells and cytotoxicity by modulation of transcription factors NF-B and AP-1 in abnormal cancer cells," Food and Chemical Toxicology, vol. 46, no. 4, pp. 1257-1270, 2008.